Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CAI
HoldPremium GrowerCaris Life Sciences, Inc. · Healthcare · United States · $7.2B · Avg Vol: $132M/d
COMPANY DESCRIPTION
Caris Life Sciences, Inc. is a precision oncology company offering molecular profiling services and AI-driven diagnostics for cancer, guiding personalized treatment decisions. Its proprietary AI platform (Caris AI) and extensive real-world clinical data set allow for deep insights into tumor biology, differentiating its diagnostic capabilities. Caris is a pioneer in precision medicine, advancing cancer diagnostics and therapeutic selection through advanced molecular profiling and artificial intelligence.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 258.5M | 306.1M | 412.3M | 812.0M | 46.5% | 989.6M | 1.0B | 1.2B | 22.3% |
| EPS | -1.57 | -1.82 | -1.36 | -3.22 | — | 9.58 | — | — | — |
| Shares | 277.9M | 277.9M | 277.9M | 282.5M | +1.7% | 282.7M | — | — | — |
| Debt | 270.9M | 217.1M | 424.3M | 427.7M | 16.4% | 452.4M | — | — | — |
| Equity | -1.7B | -2.1B | -2.5B | 577.3M | — | — | — | — | — |
| Op CF | -285.7M | -276.1M | -245.2M | 83.2M | — | 168.6M | — | — | — |
| Inv CF | -283.0M | 214.8M | 52.9M | -16.3M | — | — | — | — | — |
| Fin CF | 10.4M | 10.1M | 200.3M | 665.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CAI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CAI | Caris Life Sciences, Inc.(you) | $7.2B | 60 | Hold |
| TGTX | TG Therapeutics, Inc. | $8.3B | 57 | Hold |
| TVTX | Travere Therapeutics, Inc. | $6.2B | 54 | Hold |
| LGND | Ligand Pharmaceuticals Incorporated | $5.6B | 67 | Buy |
| BMRN | BioMarin Pharmaceutical Inc. | $12.5B | 63 | Hold |
| KRYS | Krystal Biotech, Inc. | $10.4B | 74 | Buy |
| BLTE | Belite Bio, Inc | $6.1B | 42 | Hold |
| PTGX | Protagonist Therapeutics, Inc. | $9.3B | 44 | Hold |
| CORT | Corcept Therapeutics Incorporated | $12.3B | 71 | Buy |
| TECH | Bio-Techne Corporation | $11.3B | 76 | Buy |
Peer medians: ROE -30.8% · P/E 27.1x · Gross margin 58.1%